Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
News|Articles|April 15, 2014
- Pharmaceutical Technology-04-15-2014
- Volume 2014 eBook
- Issue 1
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
Author(s)Sascha Jautze
A study investigated the influence and correlation of critical process parameters for the optimization of in-process curing.
Advertisement
Previous studies with EUDRAGIT NM 30 D showed that storage stability can be achieved with in-process curing at specific conditions. The aim of this study was to identify and investigate the influence and correlation of critical process parameters for the optimization of in-process curing.
Download
.
Articles in this issue
over 12 years ago
Continuous Manufacturing for Solid-Dosage Drug Productionover 12 years ago
Using Modular Systems in Solid-Dosage Manufacturingover 12 years ago
Advances in Hot-Melt Extrusion Manufacturingover 12 years ago
Selection of Excipients in Generic FormulationsAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5